Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer – a plain language summary

Q: How does OCRA curate its research paper database?

OCRA indexes peer-reviewed papers from PubMed and CrossRef, enriched with MeSH terms, author profiles, and citation metrics. Papers are categorized by cancer type, research method, and clinical relevance.

Q: Can I search papers by MeSH term or author?

Yes. Use the search bar to filter papers by MeSH term, author name, journal, keyword, or cancer type. Each paper includes linked MeSH terms and author profiles for further exploration.

Q: How current is the paper database?

The database is updated regularly through automated ingestion from PubMed and CrossRef. Most papers appear within days of their PubMed indexing date.

doi:10.2217/fon-2023-0782

Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer – a plain language summary

Antonio González-Martín & Bradley J Monk et al. · 2024-03-19

Links

DOI PubMed

Journal

Future Oncology

Authors

Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, Whitney Graybill, Domenica Lorusso, Colleen C McCormick, Gilles Freyer, Floor Backes, Florian Heitz, Andrés Redondo, Richard G Moore, Christof Vulsteke, Roisin E O'Cearbhaill, Izabela A Malinowska, Luda Shtessel, Natalie Compton, Mansoor R Mirza, Bradley J Monk

Funding

Pathology

NCI NIH HHS

P30 CA008748